HEMERA AWARDED MARCHI+ GRANT

Hemera has been awarded the Marchi+ grant, an incentive promoted by the Italian Ministry of Enterprises and Made in Italy through the Invitalia agency, aimed at supporting the economic enhancement of European Union and international trademark registrations. This recognition marks an important step forward in the valorization of our intellectual property assets, particularly REMaST® – a trademark registered in Europe and in 12 non-European countries.

PROGRESS OF THE OBSERVATIONAL CLINICAL STUDY

Patient recruitment and monitoring activities are ongoing at the participating centers: Niguarda Hospital in Milan, Bergamo Hospital, Villa Beretta in Lecco, and the Humanitas Clinical Institute.
To date, six patients with complete sensorimotor spinal cord injury (ASIA A) have been enrolled. They are being monitored for twelve months post-trauma, with the collection of electrophysiological, sensory, and motor data, in preparation for the upcoming clinical trial in which REMaST® therapy will be administered to humans for the first time.

PROGRESS IN TECHNOLOGY TRANSFER FOR REMaST PRODUCTION

Hemera has made significant progress in the technology transfer process for the clinical-grade production of REMaST®. In collaboration with the selected Cell Factory, the necessary activities have been initiated to ensure a high-quality manufacturing process in compliance with regulatory agency standards.
The development of standardized tests to certify the efficacy of REMaST® for human use has been completed, along with the validation of quality control procedures using GMP (Good Manufacturing Practice)–compliant products authorized for clinical application in humans.